🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cologne
Clinical trial register · Germany

Clinical Trials in Cologne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Novartis Pharmaceuticals29 University of Cologne25 Janssen Research & Development, LLC21 Bristol-Myers Squibb21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Cologne

612 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
NCT04271956Richter Transformation
DrugsSonrotoclax·Zanubrutinib·Tislelizumab
German CLL Study Group
Phase 2
83
Berlin, Cologne, Dresden, Essen, Kiel, Landshut, Paderborn, Rostock
2020-02-19
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944Non-Small Cell Lung Cancer
DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
261
Heidelberg, Gauting, Immenstadt im Allgäu, Georgsmarienhütte, Göttingen, Cologne, Großhansdorf, Berlin
2020-02-17
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Lübeck, Essen, Mainz, Dresden, Bad Krozingen, Bad Oeynhausen, Bernau, Cologne
2020-01-17
Recruiting
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
NCT03969329Secondary Hyperparathyroidism
DrugEtelcalcetide
Amgen
Phase 3
24
Bonn, Cologne, Hamburg, Hanover, Heidelberg
2019-12-20
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Bevacizumab-awwb·Mvasi
Amgen
Phase 1
610
Berlin, Cologne, Dresden, Essen
2019-12-17
Active, closed
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
NCT03480334Classical Hodgkin Lymphoma
University of Cologne
Phase 2
26
Cologne
2019-12-05
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
DrugsVindesine·Busulfan·Dacarbazine·Ifosfamide
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
800
Berlin, Cologne
2019-11-05
Active, closed
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879Carcinoma, Non-Small-Cell Lung
DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 3
461
Immenstadt im Allgäu, Cologne, Berlin, Frankfurt, Georgsmarienhütte, Hamm, Heidelberg, Löwenstein
2019-11-05
Active, closed
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
NCT04111458Solid Tumors, KRAS Mutation; SOS1
DrugsBI 1701963·Trametinib
Boehringer Ingelheim
Phase 1
71
Cologne, Frankfurt am Main
2019-11-04
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Cologne, Augsburg, Berlin, Essen, Hamburg
2019-11-04
Recruiting
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
NCT04032470Essential Tremor
Boston Scientific Corporation
Observational
500
Cologne, Düsseldorf, Essen, Kiel, Marburg, Oldenburg, Würzburg
2019-10-23
Active, closed
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
NCT03970746Non Small Cell Lung Cancer
DrugsPemetrexed·Pembrolizumab
PDC*line Pharma SAS
Phase 1/2
73
Cologne, Frankfurt am Main
2019-09-10
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
701
Berlin, Cologne, Essen, Frankfurt am Main, Gauting, Halle, Hemer, Oldenburg
2019-09-04
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Cologne, Heidelberg, Munich, Ulm, Wuppertal
2019-08-20
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Sunitinib·Relatlimab·Cabozantinib
Bristol-Myers Squibb
Phase 2
1,500
Löwenstein, Munich, Nuremberg, Essen, Aachen, Berlin, Buxtehude, Cologne
2019-08-09
Recruiting
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447Glioblastoma
DrugsAZD1390·Troriluzole·Paxalisib·CCNU
Global Coalition for Adaptive Research
Phase 2/3
2,250
Cologne, Frankfurt, Heidelberg, Mannheim, Regensburg, Tübingen
2019-07-30
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 3
254
Stuttgart, Cologne, Berlin, Essen
2019-07-26
Active, closed
Transcatheter Repair of Tricuspid Regurgitation With Edwards Cardioband TR System Post Market Study (TriBAND)
NCT03779490Tricuspid Regurgitation, Tricuspid Insufficiency
Edwards Lifesciences
Observational
150
Ulm, Bad Oeynhausen, Cologne, Berlin, Bonn, Dresden, Erlangen, Göttingen
2019-07-24
Active, closed
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796Neoplasms
DrugsNiraparib·Dostarlimab·Paclitaxel·Carboplatin
Tesaro, Inc.
Phase 3
785
Amberg, Bad Homburg, Cologne, Dessau, Dresden, Essen, Frankfurt, Giessen
2019-07-18
Active, closed
SIRONA 2 Trial Heart Failure NYHA Class III
NCT04012944Heart Failure NYHA Class III
Endotronix, Inc.
Not applicable
81
Cologne, Giessen, Hanover
2019-06-26
Active, closed
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
NCT03933735Multiple Myeloma
AbbVie
Phase 1/2
220
Cologne, Münster, Dresden, Hamburg
2019-06-24
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
2,517
Aachen, Braunschweig, Cologne, Eisleben Lutherstadt, Essen, Frankfurt am Main, Gronau, Hamburg
2019-06-11
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
415
Heidelberg, Mainz, Berlin, Bochum, Buxtehude, Cologne, Dresden, Essen
2019-06-04
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Berlin, Bonn, Chemnitz, Cologne, Freiburg im Breisgau, Heidelberg, Leipzig, Lübeck
2019-04-29
Recruiting
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
NCT05906407Early-Stage Breast Cancer, Neoadjuvant Therapy
German Cancer Research Center
Observational
2,000
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg
2019-04-19
Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
NCT03876054Chronic Pain
Abbott Medical Devices
Observational
2,000
Tübingen, Ingolstadt, Cologne, Duisburg, Düsseldorf, Mönchengladbach, Lübeck, Gera
2019-03-13
Recruiting
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609Parkinson Disease, Essential Tremor, Dystonia
Boston Scientific Corporation
Observational
5,000
Cologne, Düsseldorf, Jena, Lübeck, Würzburg
2019-03-12
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Cologne
2019-03-07
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
DrugsOlaparib·Durvalumab·Paclitaxel·Bevacizumab
AstraZeneca
Phase 3
1,407
Bad Homburg, Berlin, Bielefeld, Bonn, Brandenburg, Cologne, Dresden, Düsseldorf
2019-01-04
Active, closed
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
NCT03682536Myelodysplastic Syndromes
DrugsEpoetin Alfa·Luspatercept
Celgene
Phase 3
363
Baden-Warttemberg, Berlin, Cologne, Dresden, Duisburg, Düsseldorf, Hamburg, Keil
2019-01-02
Recruiting
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal
The University of Texas Health Science Center, Houston
Observational
5,000
Cologne
2019-01-01
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab
Novartis Pharmaceuticals
Phase 3
1,882
Munich, Neuburg A.d. Donau, Unterhaching, Marburg, Cologne, Dresden, Leipzig, Barsinghausen
2018-12-28
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Tübingen, Ulm, Erlangen, Munich, München, Frankfurt am Main, Kassel, Cologne
2018-12-17
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel
AstraZeneca
Phase 3
825
Bielefeld, Cologne, Frankfurt am Main, Immenstadt im Allgäu
2018-12-06
Recruiting
Pulmonary Hemodynamics During Exercise - Research Network
NCT03954574Pulmonary Circulation Diseases
Medical University of Graz
Observational
1,500
Cologne, Giessen, Greifswald, Heidelberg, Würzburg
2018-12-01
Active, closed
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Edwards Lifesciences
Not applicable
1,247
Bad Oeynhausen, Cologne, Dresden, Essen, Giessen, Hamburg, Heidelberg, Leipzig
2018-11-30
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
DrugsAbiraterone acetate·Abemaciclib·Prednisone
Eli Lilly and Company
Phase 2/3
393
Nürtingen, Tübingen, Holzminden, Cologne, Mettmann, Münster, Wesel, Leipzig
2018-11-26
Active, closed
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677Muscle Invasive Bladder Cancer
DrugsDurvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,063
Bergisch Gladbach, Bonn, Cologne, Erlangen, Göttingen, Herne, Jena, Magdeburg
2018-11-16
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone acetate·Olaparib
AstraZeneca
Phase 3
895
Bergisch Gladbach, Bremen, Cologne, Duisburg, Freiburg im Breisgau, Heinsberg, Mettmann, Nuremberg
2018-10-31
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Berlin, Cologne, Freiburg im Breisgau, Gauting, Heidelberg, Mainz, Münster, Oldenburg
2018-09-27
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251Neovascular Age-Related Macular Degeneration
DrugPDS Implant with Ranibizumab
Hoffmann-La Roche
Phase 3
1,000
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster
2018-09-20
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796Neoplasms
Celgene
Phase 2/3
1,541
Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt, Hamburg, Heidelberg
2018-07-19
Recruiting
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276Acute Lymphoblastic Leukemia, Pediatric
DrugsBlinatumomab·Daunorubicin·Bortezomib·Cytarabine
Martin Schrappe
Phase 3
5,000
Aachen, Augsburg, Berlin, Braunschweig, Chemnitz, Cologne, Cottbus, Datteln
2018-07-15
Active, closed
Registry in Patients With Aorto-iliac or Iliac Aneurysms
NCT03606083Vascular Aneurysm
JOTEC GmbH
Observational
298
Cologne
2018-07-15
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Berlin, Cologne, Essen, Mainz, München
2018-06-26
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
DrugsBacillus Calmette-Guerin·Durvalumab
AstraZeneca
Phase 3
1,018
Berlin, Cologne, Duisburg, Hanover, Heidelberg, Marburg, Mettmann, Mühlheim An Der Ruhr
2018-05-14
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Aachen, Cologne, Dresden, Halle, Leipzig, Lübeck, Mainz
2018-05-03
Active, closed
AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System
NCT03339115Mitral Regurgitation, Mitral Valve Disease
Cardiovalve Ltd.
Not applicable
30
Bonn, Cologne, Lübeck, Mainz, München
2018-04-23
Active, closed
THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
NCT02732704Aortic Regurgitation
JenaValve Technology, Inc.
Not applicable
100
Bad Nauheim, Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg
2018-04-20
Active, closed
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458Hepatocellular Carcinoma, Liver Cancer
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
545
Aachen, Berlin, Bonn, Cologne, Essen, Frankfurt am Main, Hanover, Homburg
2018-04-18
Active, closed
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922Melanoma
DrugsRelatlimab·Nivolumab
Bristol-Myers Squibb
Phase 2/3
714
Heidelberg, Tübingen, Quedlinburg, Buxtehude, Cologne, Erfurt, Essen, Hanover
2018-04-11
By invitation
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778Neoplasms
USWM CT, LLC
Phase 1
250
Munich, Cologne
2018-04-09
Active, closed
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181Multiple Myeloma
DrugsBortezomib·Daratumumab·Venetoclax·Dexamethasone
AbbVie
Phase 2
156
Freiburg im Breisgau, Cologne
2018-04-02
Recruiting
National Network Genomic Medicine Lung Cancer, Germany
NCT05934032Carcinoma, Non-Small-Cell Lung
Prof. Dr. Juergen Wolf
Observational
30,000
Cologne
2018-04-01
Recruiting
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
NCT03949972Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Idiopathic Nephrotic Syndrome
Prof. Dr. Paul Brinkkoetter
Observational
500
Cologne, Aachen, Berlin, Bonn, Dachau, Erlangen, Essen, Heidelberg
2018-04-01
Active, closed
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801Age Related Macular Degeneration (AMD)
Frank G. Holz
Observational
718
Bonn, Cologne, Freiburg im Breisgau, Munich, Münster, Tübingen, Ulm
2018-03-26
Active, closed
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
NCT03246529Multiple Myeloma
DrugsMotixafortide·G-Csf
BioLineRx, Ltd.
Phase 3
180
Cologne
2018-03-23
Active, closed
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
NCT03333343EGFR-mutant Non-small Cell Lung Cancer
DrugsNaporafenib·Capmatinib·Gefitinib·Trametinib
Novartis Pharmaceuticals
Phase 1
105
Cologne, Essen
2018-01-29
Recruiting
ECMM Candida Registry - CandiReg
NCT03450005Invasive Candidiases
University of Cologne
Observational
2,000
Cologne
2018-01-18
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
DrugIMGN632
AbbVie
Phase 1/2
179
Cologne, Leipzig
2018-01-02
Recruiting
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
NCT03320304Treatment Resistant Depression
LivaNova
Observational
500
Bamberg, Bonn, Cologne, Essen, Frankfurt, Freiburg im Breisgau, Göttingen, Hanover
2017-12-14
Active, closed
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
NCT02984410Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
112
Cologne, Halle, Hamburg, Jena, Leipzig, München, Tübingen, Ulm
2017-11-27
Active, closed
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
DrugsLederfolin·Leucovorin Calcium·Tecentriq·Leucovorin
National Cancer Institute (NCI)
Phase 3
712
Dresden, Berlin, Bochum, Cologne, Esslingen am Neckar, Hamburg, Leipzig, Mannheim
2017-10-16
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
DrugsSorafenib·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
1,324
Aachen, Cologne, Essen, Hanover, Heidelberg, Leipzig, Mainz, München
2017-10-11
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Bad Belzig, Bochum, Cologne, Dortmund, Freiburg im Breisgau, Hanover, Leipzig, Mainz
2017-09-12
Active, closed
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
NCT03252938Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
DrugsEfti·Avelumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1
83
Bad Saarow, Cologne, Essen, Frankfurt, Giessen, Hamburg, Herne, Mainz
2017-08-15
Active, closed
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
NCT03104842Multiple Myeloma
DrugsIsatuximab·Carfilzomib·Lenalidomide·Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
Phase 2
246
Berlin, Bielefeld, Bonn, Chemnitz, Cologne, Eschweiler, Essen, Hamburg
2017-08-15
Active, closed
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
NCT03040973Advanced Solid Tumors Which Are cMET-dependent
DrugsCapmatinib·Gefitinib·Osimertinib
Novartis Pharmaceuticals
Phase 2
29
Cologne, Hanover
2017-07-04
Active, closed
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
DrugsPerjeta·Herceptin·Exemestane·Anastrozole
Alliance Foundation Trials, LLC.
Phase 3
518
Bottrop, Cologne, Essen, Frankfurt, Hanover, Kiel, Münster, Schweinfurt
2017-06-21
Recruiting
CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
NCT05652569Metastatic Breast Cancer
German Cancer Research Center
Observational
5,000
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg
2017-06-12
Active, closed
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
857
Würzburg, Cologne
2017-05-02
Active, closed
Enhancing Recovery in Early Schizophrenia
NCT02926859Schizophrenia
Central Institute of Mental Health, Mannheim
Phase 2
180
Mannheim, Munich, Berlin, Aachen, Cologne, Hamburg
2017-04-08
Active, closed
REDUCE LAP-HF III Corvia Protocol 1701
NCT03191656Heart Failure
Corvia Medical
Observational
500
Bad Nauheim, Bad Oeynhausen, Bad Segeberg, Berlin, Chemnitz, Cologne, Detmold, Dresden
2017-03-12
Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
500
Berlin, Cologne, Dresden, Heidelberg
2017-03-07
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Cologne
2016-12-15
Recruiting
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
NCT02880618Heart Failure
CVRx, Inc.
Observational
500
Hamburg, Bad Oeynhausen, Berlin, Bernau, Chemnitz, Cologne, Detmold, Dresden
2016-12-13
Recruiting
BAROSTIM THERAPY™ In Resistant Hypertension
NCT02880631Hypertension
CVRx, Inc.
Observational
500
Berlin, Bernau, Cloppenburg, Cologne, Detmold, Dresden, Erding, Frankfurt
2016-12-13
Active, closed
Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
NCT02766543Prostate Cancer
Profound Medical Inc.
Not applicable
150
Cologne, Heidelberg
2016-09-21
Recruiting
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
NCT02844049Obsessive-Compulsive Disorder
University Hospital, Grenoble
Not applicable
60
Cologne
2016-09
Recruiting
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707Community-acquired Pneumonia, Influenza, COVID-19
DrugsConvalescent plasma·Repagermanium·Ivermectin·Amoxicillin-clavulanate
UMC Utrecht
Phase 3
20,000
Berlin, Cologne, Cottbus, Dortmund, Essen, Frankfurt, Hamburg, Jena
2016-04-11
Recruiting
Vercise™ DBS Dystonia Prospective Study
NCT02686125Dystonia
Boston Scientific Corporation
Observational
300
Berlin, Cologne, Düsseldorf, Freiburg im Breisgau, Hamburg, Hamm, Hanover, Kiel
2016-03-07
Active, closed
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)
NCT02730338Metastatic Prostate Cancer
Movember Foundation
Not applicable
866
Cologne
2016-01
Active, closed
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933ALK Positive Malignancies
DrugCeritinib
Novartis Pharmaceuticals
Phase 4
233
Regensburg, Cologne, Essen, Heidelberg, Würzburg
2015-12-11
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
DrugsHumira·Adalimumab·Upadacitinib
AbbVie
Phase 3
1,629
Cologne, Herne, Rendsburg, Chemnitz, Hamburg, Munich
2015-12-01
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
DrugEntrectinib
Hoffmann-La Roche
Phase 2
534
Berlin, Cologne, Göttingen, Heidelberg
2015-11-19
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,400
Munich, Regensburg, Würzburg, Frankfurt am Main, Cologne, Leipzig, Berlin, Hamburg
2015-11-02
Recruiting
The German ADPKD Tolvaptan Treatment Registry
NCT02497521ADPKD (Autosomal Dominant Polycystic Kidney Disease)
University of Cologne
Observational
2,000
Müllheim, Würzburg, Hanover, Cologne, Nettetal, Leipzig, Lübeck, Berlin
2015-11
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
DrugOsimertinib
AstraZeneca
Phase 3
682
Aachen, Berlin, Cologne, Coswig, Gauting, Gerlingen, Großhansdorf, Halle
2015-10-21
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt, Hamburg, Hanover
2015-07
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
DrugsGefitinib·Erlotinib·Ramucirumab·Osimertinib
Eli Lilly and Company
Phase 3
545
Gerlingen, Heidelberg, Cologne, Chemnitz, Halle, Großhansdorf, Berlin
2015-05-06
Recruiting
German Centre for Infection Research HIV Translational Platform
NCT02149004HIV
University Hospital of Cologne
Observational
10,000
Cologne
2015-04
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Cologne, Jena, Heidelberg
2015-03-06
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bad Reichenhall, Würzburg, Bochum, Düsseldorf, Dresden, Berlin, Cologne, Giessen
2015-01-20
Recruiting
International HIT-MED Registry (I-HIT-MED)
NCT02417324Childhood Brain Tumor
Universitätsklinikum Hamburg-Eppendorf
Observational
500
Aachen, Augsburg, Berlin, Bielefeld, Braunschweig, Bremen, Chemnitz, Cologne
2015-01
Active, closed
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251Diffuse Large B-cell Lymphoma
DrugSelinexor
Karyopharm Therapeutics Inc
Phase 2
244
Aachen, Bad Saarow, Berlin, Bremen, Cologne, Dresden, Halle, Hanover
2014-11
Active, closed
PERIGON Pivotal Trial
NCT02088554Aortic Stenosis
Medtronic Cardiac Surgery
Not applicable
1,312
Cologne, Munich, Frankfurt, Hanover, Leipzig
2014-05-12
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134Parkinson's Disease
Boston Scientific Corporation
Observational
1,500
Berlin, Cologne, Düsseldorf, Freiburg im Breisgau, Hamburg, Hamm, Kiel, Mainz
2014-03-04
Active, closed
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204Prostatic Neoplasms
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Aachen, Bergisch Gladbach, Berlin, Braunschweig, Cologne, Duisburg, Emmendingen, Frankfurt am Main
2013-10-14
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
DrugsPegylated G-CSF·Pegfilgrastim·Selumetinib·Docetaxel
AstraZeneca
Phase 3
510
Augsburg, Bad Berka, Cologne, Dortmund, Gerlingen, Großhansdorf, Halle, Heidelberg
2013-09-25
Recruiting
Pediatric Arm of DZL All Age Asthma Cohort
NCT02496468Asthma, Wheeze, Hypersensitivity, Endophenotype
LMU Klinikum
Observational
1,500
Cologne, Hanover, Lübeck, Marburg, Munich
2013-01
Rows per page Showing 501–600 of 612
Previous 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/cologne?page=6

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Cologne.

How many clinical trials are recruiting in Cologne?

312 of the 612 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 27 have not yet opened recruitment, 261 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.